Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation – September

OIS European Innovation Showcase

OIS Dry Eye Innovation Showcase Presentation

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 21, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021 , Vicente Anido , PhD.
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 20, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease
AR-15512 (0.003%) BID Advancing to Phase 3; No Treatment-Related Serious or Systemic Adverse Events Reported Conference Call and Webcast Today, September 15 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2021-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2021-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
TOP